Targovax plans checkpoint combo trial after posting early data on oncolytic virus

Targovax plans checkpoint combo trial after posting early data on oncolytic virus

Source: 
Fierce Biotech
snippet: 

Targovax has shared data from an early-phase trial that administered ONCOS-102 to mesothelioma patients. The response rate was lower in the ONCOS-102 arm than in the control cohort, but Targovax saw positives elsewhere, leading it to outline plans to pair the drug with a checkpoint inhibitor.